Earnings History Data for Lipocine Inc. (LPCN) - NYSE NASDAQ
To lookup another company type a stock symbol and press 'Go'. The overview will show the earnings release info that is available in TheStockCatalyst database for the company.
For historic stock the Extended Hours price data shown are from just before market open on the day of release for premarket earnings releases and of the day after release for afterhours earnings releases. The normal price data is from just before market close on the days of release for premarket releases and the day after release for afterhours releases.
For historic stock the Extended Hours price data shown are from just before market open on the day of release for premarket earnings releases and of the day after release for afterhours earnings releases. The normal price data is from just before market close on the days of release for premarket releases and the day after release for afterhours releases.
See the full list of available companies here.
Lipocine Inc.
Lipocine, Inc. is a specialty pharmaceutical company. It develops pharmaceutical products for use in men's and women's health. The Company's lead product candidate, LPCN 1021, is in Phase 3 and is targeted to treat symptoms of low testosterone for men in need of testosterone replacement therapy. Its additional pipeline candidates include LPCN 1111, a next generation oral testosterone therapy product, and LPCN 1107, indicated for the prevention of preterm birth and is currently in Phase 1. Lipocine Inc. is headquartered in Salt Lake City, Utah.
| Release Date | Time | Est. Time | Symbol | Name | Market Cap (M) | Rep. EPS | Est. EPS | Last years EPS | SeekingAlpha Headline | Price | Change | Ext. Hours Price | Ext. Hours Change | 52 Week Range | Volume | Avg. Volume | Ext. Hours Volume | Top Mover |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 07-03-2024 | PM | LPCN | Lipocine | 19.00 | -0.42 | -0.53 | 0.00 | Lipocine GAAP EPS of -$3.14 [3/7/2024 11:17 AM] |
3.63 | 0.05 (1.40%) |
0.0 | 0.0 (0.00%) |
2.31 - 7.87 | 33,834 | 10,000 | 0 | ||
| 10-08-2023 | PM | LPCN | Lipocine | 26.00 | -0.68 | -0.64 | 0.00 | Lipocine GAAP EPS of -$0.68 misses by $0.04 [8/10/2023 11:04 AM] |
5.04 | -0.05 (-1.08%) |
0.0 | 0.0 (0.00%) |
3.30 - 12.75 | 23,631 | 950,000 | 0 | ||
| 08-08-2022 | PM | 8:00 AM ET (Aug 8) |
LPCN | Lipocine | 72.00 | -0.04 | -0.04 | 0.00 | Lipocine GAAP EPS of -$0.04 in-line, revenue of $0.5M beats by $0.24M [8/8/2022 8:36 AM] |
0.7329 | -0.09 (-10.94%) |
0.80 | -0.02 (-2.78%) |
0.71 - 1.89 | 816,749 | 140,000 | 338 | |
| 09-03-2022 | PM | 8:00 AM ET (Mar 9) |
LPCN | Lipocine | 133.00 | 0.15 | -0.05 | 0.00 | Lipocine GAAP EPS of -$0.01, revenue of $16.1M [3/9/2022 9:08 AM] |
1.51 | 0.10 (7.09%) |
1.50 | 0.09 (6.38%) |
0.80 - 2.03 | 470,554 | 890,000 | 68,640 | |
| 10-11-2021 | PM | LPCN | Lipocine Inc. | 104.18 | -0.03 | -0.05 | -0.07 | Lipocine EPS beats by $0.01 [11/10/2021 8:09 AM] |
1.16 | -0.03 (-2.52%) |
1.19 | 0.0 (0.00%) |
0.98 - 2.42 | 418,946 | 970,000 | 5,365 | ||
| 06-05-2021 | PM | 8:00 AM ET (May 6) |
LPCN | Lipocine Inc. | 121.84 | -0.04 | 0.00 | -0.14 | Lipocine EPS beats by $0.01 [5/6/2021 8:43 AM] |
1.36 | -0.03 (-2.16%) |
1.38 | -0.01 (-0.72%) |
0.57 - 2.42 | 828,857 | 730,000 | 2,508 | |
| 11-03-2021 | PM | LPCN | Lipocine Inc. | 121.00 | -0.06 | -0.06 | 0.00 | Lipocine EPS misses by $0.01 [3/11/2021 9:18 AM] |
1.66 | 0.16 (11.07%) |
1.53 | 0.04 (2.68%) |
0.30 - 2.42 | 2,267,951 | 2,494,742 | 77,128 | ||
| 10-11-2020 | PM | LPCN | Lipocine Inc. | 86.70 | -0.07 | -0.05 | -0.12 | Lipocine EPS misses by $0.01 [11/10/2020 8:03 AM] |
1.38 | -0.05 (-3.45%) |
1.40 | -0.03 (-2.10%) |
0.30 - 2.39 | 1,153,618 | 1,058,262 | 39,021 | ||
|
|
||||||||||||||||||
| 06-08-2020 | PM | LPCN | Lipocine Inc. | 73.73 | -0.13 | -0.07 | -0.14 | Lipocine EPS misses by $0.06 [8/6/2020 9:08 AM] |
1.84 | -0.12 (-6.38%) |
1.91 | -0.05 (-2.56%) |
0.30 - 3.45 | 4,080,202 | 3,887,376 | 546,318 | ||
|
|
||||||||||||||||||